An adjuvant is a substance added to vaccines to enhance immune response. Its inclusion reduces the dose of antigen required, thus producing more doses of vaccine with the same amount of antigen.
The vaccine against seasonal influenza does not typically contain an adjuvant. Some, however, contain an oil in water emulsion containing squalene (MF59 of Novartis).
Vaccines against influenza A (H1N1) occurred either without adjuvant (especially the U.S.) with an adjuvant containing squalene (especially in Europe).
The vaccine against seasonal influenza does not typically contain an adjuvant. Some, however, contain an oil in water emulsion containing squalene (MF59 of Novartis).
Vaccines against influenza A (H1N1) occurred either without adjuvant (especially the U.S.) with an adjuvant containing squalene (especially in Europe).
Squalene, said WHO is a substance found naturally in plants, animals and humans. In humans, it is synthesized in the liver. It is commercially extracted from fish oil.
"Since 1997, 22 million doses of flu vaccine from Chiron (the FLUAD) were administered without safety concerns. The vaccine contains about 10 mg of squalene per dose and he was not associated with any serious adverse reaction. It has been observed some moderate local reactions, "says the WHO.
The effects of this adjuvant, however, are little known on special populations such as pregnant women, immunocompromised persons or very young children. The High Council of Public Health (HCSP) recommends the use of non-adjuvanted vaccines for children 6 to 23 months, pregnant women and immunocompromised individuals.
In Canada, GlaxoSmithKline will provide a version without adjuvant, which will be offered to pregnant women.
"Since 1997, 22 million doses of flu vaccine from Chiron (the FLUAD) were administered without safety concerns. The vaccine contains about 10 mg of squalene per dose and he was not associated with any serious adverse reaction. It has been observed some moderate local reactions, "says the WHO.
The effects of this adjuvant, however, are little known on special populations such as pregnant women, immunocompromised persons or very young children. The High Council of Public Health (HCSP) recommends the use of non-adjuvanted vaccines for children 6 to 23 months, pregnant women and immunocompromised individuals.
In Canada, GlaxoSmithKline will provide a version without adjuvant, which will be offered to pregnant women.
0 comments:
Post a Comment